Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma

Inclusion Criteria: * Histologically confirmed diagnosis of relapsed/refractory MCL or hematologically/bone marrow confirmed relapsed/refractory CLL that is not amenable to cure by surgery or other means and has failed at least 1 prior systemic therapy; * Subjects may have been treated with up to 6 prior systemic therapies for relapsed/refractory disease or have become intolerant to a systemic therapy * For MCL, must have measurable disease * At least 4 weeks since the last systemic therapy, including RT, for the treatment of MCL/CLL; * At least 4 weeks since taking any corticosteroids prior to the first dose of MDX-1411 * ECOG Performance Status 0 to 2; * No known positivity for human immunodeficiency virus (HIV) and no active infection with Hepatitis B or Hepatitis C; Exclusion Criteria: * History of severe hypersensitivity reactions to other monoclonal antibodies; * Use of other investigational drugs within 30 days before study drug administration * Prior treatment with any other anti-CD70 antibody; * Active infection requiring i.v. systemic therapy within 4 weeks of receiving the first dose of MDX-1411; * Evidence of bleeding diathesis or coagulopathy; * Active autoimmune disease requiring immunosuppressive therapy; * Known current drug or alcohol abuse; * Underlying medical conditions that will make the administration of MDX-1411 hazardous